Nat Commun:影响早睡早起的基因变异

2019-02-01 Nature自然科研 Nature自然科研

《自然-通讯》本周发表的一篇论文Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms指出,遗传变异会影响一个人是否是晨型人(morning person),并且会给心理健康带来潜在后果。这一大规模全基因组关联分析在之前研究的基础上进

《自然-通讯》本周发表的一篇论文Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms指出,遗传变异会影响一个人是否是晨型人(morning person),并且会给心理健康带来潜在后果。这一大规模全基因组关联分析在之前研究的基础上进行了拓展,将与睡眠时型(在特定时间睡觉的先天倾向)可能相关的基因座总数从24个增加到351个。



睡眠时型荟萃分析GWAS的曼哈顿图。

英国埃克塞特大学医学院的Michael Weedon及同事分析了两组人群(共697828人)的遗传变异,并寻找这些变异与自我报告的晨型程度之间的关系。在鉴定出的所有基因座中,有327个此前与睡眠时型并不相关。考虑到自我报告存在不准确或偏倚的情况,为了进一步验证这一发现,作者利用活动监测器对一部分参与者(共85760人)的睡眠情况进行了客观监测。结果证实,睡眠时型的基因座与入睡时间有关,但与睡眠质量和睡眠时间无关。作者使用多种统计方法研究了睡眠时型与疾病之间的关系,发现晨型人主观幸福感较强,同时抑郁症和精神分裂症风险较低。



主观幸福感与睡眠时型暴露的孟德尔随机化散点图。

作者指出大部分研究结果都基于自我报告(即问卷回答),可能会受到报告偏差的影响。因此,需要进一步研究才能确认这些遗传变异对患病风险是否具有因果作用。

原始出处:
Samuel E. Jones, Jacqueline M. Lane, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications. 29 Jan 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087511, encodeId=e1f9208e5112d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 27 00:01:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883576, encodeId=d85518835e6f7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 29 09:01:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314174, encodeId=74bd13141e4bf, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342557, encodeId=fde8134255e87, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-27 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087511, encodeId=e1f9208e5112d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 27 00:01:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883576, encodeId=d85518835e6f7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 29 09:01:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314174, encodeId=74bd13141e4bf, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342557, encodeId=fde8134255e87, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-06-29 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087511, encodeId=e1f9208e5112d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 27 00:01:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883576, encodeId=d85518835e6f7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 29 09:01:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314174, encodeId=74bd13141e4bf, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342557, encodeId=fde8134255e87, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087511, encodeId=e1f9208e5112d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Feb 27 00:01:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883576, encodeId=d85518835e6f7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jun 29 09:01:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314174, encodeId=74bd13141e4bf, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342557, encodeId=fde8134255e87, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Feb 03 00:01:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]

相关资讯

急重症科:优化ICU睡眠

睡眠障碍在ICU病人中很常见。虽然造成这一现象的许多原因是无法改变的,而其他部分睡眠障碍原因则依赖于基础疾病的潜在条件的改善,但有许多原因则直接依赖于治疗团队的行动:例如,噪音暴露在噪音中、治疗操作的时机、逐渐减少镇静药物逐渐减剂量以及白天的活动。一些病人可能会受益于夜间镇静,但有合理证据表明苯二氮卓类和丙泊酚不是最佳选择。虽然尚未得到在大型临床试验中还没有得到的证实,但包括右美托咪定、褪黑素(和

Sports Medicine:晚上适度运动不影响睡眠,但睡前1小时不要剧烈运动

根据运动指南的建议,每周至少要做150分钟的适度运动。很多人鉴于白天没有时间,而不得不选择晚上锻炼,但又担心对睡眠产生负面影响

[重复]Eur Heart J:阜外医院李卫团队PURE研究发现:每天睡觉超9小时,该警惕;睡不够6小时,白天可小睡

昨日,欧洲心脏杂志刊登了阜外医院李卫教授团队与加拿大Salim Yusuf教授等人联合开展的PURE研究的最新分析。 研究表明,成年人每天睡6~8小时心血管病和死亡风险最低,但每天睡8小时以上,心血管病和死亡却较高。

JACC:睡眠不足与动脉粥样硬化风险增高呈独立相关性!

睡眠时间和质量与心血管危险因素的增加呈相关性,本研究的目的旨在评估活动心电图测量的睡眠参数与亚临床动脉粥样硬化的相关性,并且评估睡眠、传统危险因素、社会心理因素和炎症之间的相互作用。本研究对PESA临床研究中的3974名(平均年龄45.8 ± 4.3,男性占62.6%)参与者进行了7天的睡眠活动记录,并将其分为睡眠时间很少(<6 h)、少(6-7h)、良好(7-8h)和长(>8h)四组,睡眠

Support Care Cancer:前列腺癌患者中伴随的睡眠问题研究

最近,有研究人员调查了前列腺癌生存者的睡眠问题的流行程度,并且探索了该过程中的诱发因素、沉淀因素和永久因素。研究是一个代表性的研究,包括了3348名前列腺癌幸存者。这些幸存者报道在诊断后2到18年具有失眠的经历,同时也调查了他们的社会人口特征、健康状态和接受的治疗方法。研究发现,19%的幸存者报道具有明显的睡眠问题。最后的模型能够解释失眠评分变化的31%(p<0.001)。按照影响大小排序,

Science :一夜没睡,患阿尔茨海默症风险或升高

长期以来,睡眠不足一直被认为与阿尔茨海默症(Alzheimer’s disease)有关,但研究人员对睡眠不足如何导致这种疾病却知之甚少。此前已有研究证明,睡眠问题和阿尔茨海默症在一定程度上与该疾病的标志蛋白质β淀粉样蛋白相关。